Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences

Rhea-AI Summary

Fusion Pharmaceuticals Inc. will participate in two upcoming investor conferences: the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, and the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023. The presentations will be given by Chief Financial Officer John Crowley and Chief Executive Officer John Valliant, Ph.D., respectively. Webcasts of each event will be available on the company's website, and a replay will be archived for 90 days.

HAMILTON, ON and BOSTON, Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences.

• The H.C. Wainwright 25th Annual Global Investment Conference – The Company presentation will take place on Tuesday, September 12, 2023 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Financial Officer John Crowley.
• The Morgan Stanley 21st Annual Global Healthcare Conference – The fireside chat will take place on Wednesday, September 13, 2023 at 3:35 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Webcasts of each event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical.

Contact:
Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-upcoming-september-investor-conferences-301918260.html

SOURCE Fusion Pharmaceuticals

FAQ

What is the name of the company participating in the investor conferences?

The company participating in the investor conferences is Fusion Pharmaceuticals Inc.

When and where will the H.C. Wainwright 25th Annual Global Investment Conference take place?

The H.C. Wainwright 25th Annual Global Investment Conference will take place on Tuesday, September 12, 2023, at 2:00 p.m. ET.

Who will be presenting on behalf of Fusion at the H.C. Wainwright conference?

Chief Financial Officer John Crowley will be presenting on behalf of Fusion at the H.C. Wainwright conference.

When and where will the Morgan Stanley 21st Annual Global Healthcare Conference take place?

The Morgan Stanley 21st Annual Global Healthcare Conference will take place on Wednesday, September 13, 2023, at 3:35 p.m. ET.

Who will be presenting on behalf of Fusion at the Morgan Stanley conference?

Chief Executive Officer John Valliant, Ph.D., will be presenting on behalf of Fusion at the Morgan Stanley conference.

Where can I find the webcasts of the conferences?

The webcasts of the conferences can be found on the 'Events and Presentations' page in the 'Investors & Media' section of Fusion Pharmaceuticals Inc.'s website at https://ir.fusionpharma.com/events-webcasts.

How long will the webcast replays be available?

The webcast replays will be archived on Fusion Pharmaceuticals Inc.'s website for 90 days following their respective presentation dates.